PIIND2024-10-012024-12-31 PIIND2024-10-012024-12-31 PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses03Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses04Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses05Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses06Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses07Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses08Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses09Member PIIND2024-10-012024-12-31in-bse-fin:OneOperatingExpenses10Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses03Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses04Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses05Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses06Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses07Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses08Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses09Member PIIND2024-10-012024-12-31in-bse-fin:FourOperatingExpenses10Member PIIND2024-12-31 PIIND2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member PIIND2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member PIIND2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member PIIND2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member PIIND2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member PIIND2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member PIIND2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member PIIND2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member PIIND2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member PIIND2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member PIIND2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member PIIND2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member PIIND2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member PIIND2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member PIIND2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member PIIND2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member PIIND2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member PIIND2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member PIIND2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member PIIND2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 523642 PIIND NOTLISTED PI Industries Limited Equity 2024-04-01 2025-03-31 2025-02-06 2025-01-24 INR Millions Third quarter 14:00:00 17:15:00 2025-02-06 2025-02-06 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Consolidated 19008000000.00 759000000.00 19767000000.00 7874000000.00 437000000.00 679000000.00 1910000000.00 83000000.00 991000000.00 2988000000.00 14962000000.00 4805000000.00 0.00 4805000000.00 864000000.00 216000000.00 1080000000.00 0.00 3725000000.00 0.00 0.00 0.00 2000000.00 3727000000.00 -549000000.00 3178000000.00 3178000000.00 0.00 3178000000.00 0.00 152000000.00 1 24.55 24.55 0.00 0.00 24.55 24.55 1 The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on February 06, 2025. 2 The Consolidated Financial results for all the periods presented have been prepared in accordance with Iha recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3 The Consolidated financial results include the results of the following entities namely, Parent Company - Pl Industries Limited; Subsidiaries (Including step down subsidiaries): (a) Pl Health Sciences Limited (b) Pl Health Sciences USA, LLC (c) Pl Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) Plant Health Care limited (f) Plant Health Care, Inc, Nevada (g) Plant Health Care de Mexico S. de R.L. de C.V. (h) Plant Health Care (UK) Limited (i) Plant Health Care Espana (j) Plant Health Care In sumos Agrlcolas L TDA (kl Jlvagro Limited (I) Pl Life Science Research Limited (m) Pl Industries Management Consultancies L.L.C Dubai (n) PILL Finance and Investments Limited (o) Pl Japan Co. Limited (p) Pl Bioferma Private Limited (q) Pl Fermachem Private Limited ;Controlled trust - Pl ESOP Trust; Joint Ventures - (a) Pl Kumiai Private Limited (b) Pl Flowtech B.V. ; Associate Solinnos Agro Sciences Private Limited. 4 During the quarter ended September 30, 2024, the Company ( Pl Industries Ltd. ) had acquired the entire share capital of Plant Health Care Pie, a England and Wales incorporated Company through its wholly owned subsidiary, Pl Industries Management Consultancies L.L.C. , Dubai. This acquisition is effective from August 20, 2024 pursuant to a court sanctioned scheme of arrangement. This transaction has been accounted for in accordance with the acquisition method specified In Ind AS 103 Business Combination . Out of the total purchase consideration of Rs. 3,639 Mn, Rs. 1,696 Mn, representing excess of the provisional fair value of the net assets acquired, has been recognised as provisional goodwlll, subject to finalisation. 5 The Company raised Rs. 20,000 Mn during the quarter ended September 30, 2020 through Qualified Institutional Placement (QIP) of equity shares. Out of the funds received of Rs. 19,750 Mn (net of expense of Rs. 250 Mn), the Company invested Rs. 16,105 Mn in its subsidiaries. Balance funds of Rs. 3,645 Mn received pursuant to QIP remain invested in liquid and other debt mutual funds. 6 Segment information as per Ind AS 108 Operating Segments is as per Annexure I. 7 The Board of Directors at their meeting held on February 06, 2025 have approved the interim dividend of Rs. 6.00 per equity share of face value of Re. 1.00 each for the financial year 2024-25. Multi segment 2024-04-01 2024-12-31 Unaudited Consolidated 61907000000.00 2708000000.00 64615000000.00 25515000000.00 1530000000.00 2636000000.00 5867000000.00 251000000.00 2623000000.00 9125000000.00 47547000000.00 17068000000.00 0.00 17068000000.00 3248000000.00 553000000.00 3801000000.00 0.00 13267000000.00 0.00 0.00 0.00 30000000.00 13297000000.00 -582000000.00 12715000000.00 12715000000.00 0.00 12715000000.00 0.00 152000000.00 1 87.65 87.64 0.00 0.00 87.65 87.64 Advertisement & Sales Promotion 243000000.00 Environment & Pollution Control Expenses 326000000.00 Freight & Cartage 214000000.00 Laboratory & Testing Charges 86000000.00 Legal & professional fees 292000000.00 Net Impairment losses on Financial Assets 13000000.00 Others 633000000.00 Power, Fuel & Water 614000000.00 Repairs & Maintenance 311000000.00 Travelling and Conveyance 256000000.00 Advertisement & Sales Promotion 596000000.00 Environment & Pollution Control Expenses 1007000000.00 Freight & Cartage 492000000.00 Laboratory & Testing Charges 384000000.00 Legal & professional fees 881000000.00 Net Impairment losses on Financial Assets 304000000.00 Others 1938000000.00 Power, Fuel & Water 1941000000.00 Repairs & Maintenance 881000000.00 Travelling and Conveyance 701000000.00 Agro Chemicals 18381000000.00 Pharma 637000000.00 Agro Chemicals 60619000000.00 Pharma 1301000000.00 19018000000.00 61920000000.00 10000000.00 13000000.00 19008000000.00 61907000000.00 Agro Chemicals 5366000000.00 Pharma -559000000.00 Agro Chemicals 18925000000.00 Pharma -1827000000.00 4807000000.00 17098000000.00 0.00 0.00 0.00 Notes: The business of the group devided into two segments as below: a) Agro Chemical Agro Chemicals includes Agchem(CSM), Domestic Agri Brands. b) Pharma Pharma comprises contract research and Development, contract development and Manufacturing of active, key starting materials and intermediates used in pharmaceutical industry. 0.00 4807000000.00 17098000000.00 Agro Chemicals 107774000000.00 Pharma 12955000000.00 120729000000.00 Agro Chemicals 18598000000.00 Pharma 3471000000.00 22069000000.00 0.00 22069000000.00 Remeasurements gain/(loss) on cash flow hedges -24000000.00 Remeasurements gain/(loss) on cash flow hedges -71000000.00 -24000000.00 -71000000.00 -9000000.00 -26000000.00 Effective portion of gain/(loss) on cashflow hedges -559000000.00 Exchange difference on translation of foreign operations -163000000.00 Effective portion of gain/(loss) on cashflow hedges -782000000.00 Exchange difference on translation of foreign operations -27000000.00 -722000000.00 -809000000.00 -188000000.00 -272000000.00